<DOC>
	<DOCNO>NCT01302145</DOCNO>
	<brief_summary>A study investigate effect safety , pharmacokinetics pharmacodynamics ASP1941 administer add-on therapy metformin .</brief_summary>
	<brief_title>Drug Drug Interaction Study With ASP1941 Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Subjects type 2 diabetes Stable disease metformin monotherapy ( 15003000 mg/day ) dual therapy metformin ( 15003000 mg/day ) Sulfonylureum Derivative ( SUD ) least 3 month Fasting Serum Glucose : 711.5 mmol/l ( washout ) Stable Fasting Blood Glucose ( FBG ) end washout BMI 18.5 40.0 kg/m2 , inclusive Subjects type 1 diabetes Any diabetes related macrocomplications , painful diabetic neuropathy , diabetic macular edema diabetic proliferative retinopathy Clinical significant renal disease ( CLcr &lt; 60 ml/min assess 24h creatinine clearance Day2 Recent evidence ( e.g . within last 6 month ) severe hypoglycemia , example plasma glucose &lt; 3 mmol/l ( &lt; 55 mg/dl ) require hospitalization Pulse &lt; 40 &gt; 90 ; Systolic Blood Pressure &gt; 160 mmHg ; Diastolic Blood Pressure &gt; 100 mmHg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>ASP1941</keyword>
	<keyword>Drug drug interaction</keyword>
	<keyword>metformin</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>